Parkinson's disease (PD)


Our current research focuses on:


Alpha Synuclein

The accumulation of aggregated alpha-synuclein within Lewy bodies and Lewy neurites is the defining feature of idiopathic PD.

Imaging Agents

An alpha-synuclein imaging agent would improve the diagnosis of Parkinson disease and could be used to monitor the effectiveness of disease-modifying treatments.

Loss of Connections

The relationship between the loss of neuronal connections and non-motor PD symptoms could result in better treatments.


Developing treatments that slow or stop the accumulation of alpha-synuclein fibrils in the brain could slow or stop the progression of Parkinson Disease.

Infantile Neuroaxonal Dystrophy (INAD)

Our current research focuses on:


Enzyme Function

Investigating the ways in which mutations responsible for INAD and PKAN affect the function of the enzymes encoded by the PLA2G6 and PANK2 genes.


Developing treatments that improve the function of enzymes affected by disease-causing mutations and that compensate for the loss of enzyme function.

Dr. Kotzbauer also sees patients in the Movement Disorders Center at Washington University School of Medicine.

To contact the Movement Disorders Center click here.